参桃软肝丸抑制人肝癌细胞增殖及增强LAK抑瘤活性的实验研究

The Experimental Research of the Suppression of Shentao Ruangan Wan on the Proliferation of Human HCC and the Improvement in the Anticancer Activity of LAK Cell

目的:研究中药复方参桃软肝丸对人肝癌细胞BEL-7402、SMMC-7721增殖的影响,探讨其抗癌作用机制。方法:参桃软肝丸灌胃给药后,采集大鼠血清,处理人肝癌细胞BEL-7402、SMMC-7721,MTT法观察细胞增殖;并与淋巴因子激活的杀伤细胞(LAK)共同处理以上两种细胞。结果:参桃软肝丸具有显著抑制BEL-7402、SMMC-7721增殖的作用,且存在不同浓度之间的差异,呈现出血清浓度依赖性,它可以显著提高LAK抑制BEL-7402、SMMC-7721增殖的活性。结论:抑制人肝癌细胞增殖,提高LAK活性可能是参桃软肝丸抗肝癌的主要作用机制。

Objective: To observe the influence of Shentao Ruangan Wan (a kind of traditional Chinese medicine) on the proliferation of human HCC BEL-7402, SMMC-7721, so as to discuss its anticancer mechanisms. Method: The method we used is to obtain pharmaceutic serum of the rats after being given the drug by stomach, then mix the serum with HCC BEL-7402, SMMC-7721 and observe their proliferation by MTT; furthermore we treated these two kind of cells together with LAK cell. Results: Shentao Ruangan Wan suppressed the proliferation of HCC BEL-7402. SMMC-7721 markedly, it indicated a serum-concentration dependence from to which extent the cells were suppressed. Conclusion : The main pharmacologic mechanisms of Shentao Ruangan Wan are perhaps the suppression of the proliferation of human HCC and the activation of LAK cells.